Category BUSINESS

Ashland Expands Injectables Portfolio with High-Purity Sucrose and Low-Nitrite Excipients

Ashland is spotlighting multiple new and optimized pharmaceutical product offerings during CPHI Frankfurt, October 28-30 (booth 8.0Q48) and AAPS PharmSci 360, San Antonio, TX, November 9-12 (booth 2808). To respond to global customer needs, Ashland has introduced vialose™ sucrose, a…

Read MoreAshland Expands Injectables Portfolio with High-Purity Sucrose and Low-Nitrite Excipients

BASF Opens NPG Plant in Zhanjiang, Launches Low-Carbon NEOL® NPG

BASF expands its presence in China with a new high-efficiency NPG plant powered by renewable energy, delivering lower-carbon intermediates for eco-friendly coatings BASF’s Intermediates division has inaugurated a new neopentyl glycol (NPG) plant at the Verbund site in Zhanjiang, China. Following the start-up of the new plant with an annual production…

Read MoreBASF Opens NPG Plant in Zhanjiang, Launches Low-Carbon NEOL® NPG

Air Products Completes First Liquid Hydrogen Fill at World’s Largest Sphere at NASA

Air Products Completes Historic First Liquid Hydrogen Fill of World’s Largest Storage Sphere at NASA’s Kennedy Space Center Air Products (NYSE: APD), the global leader in hydrogen supply, announced a major milestone in its long-standing partnership with NASA: the successful…

Read MoreAir Products Completes First Liquid Hydrogen Fill at World’s Largest Sphere at NASA
Kinea Bio Advances Dysferlinopathy Gene Therapy with $1.1M

Kinea Bio Advances Dysferlinopathy Gene Therapy with $1.1M Investment, Solid Biosciences Deal

Kinea Bio Inc., a biotechnology company dedicated to developing transformative genetic medicines, announced today two major milestones that significantly advance its lead gene therapy program for dysferlinopathy, a rare and debilitating neuromuscular disease. The company has secured a commitment of…

Read MoreKinea Bio Advances Dysferlinopathy Gene Therapy with $1.1M Investment, Solid Biosciences Deal
Immuto Secures $8M Seed 2 Funding, Partners

Immuto Secures $8M Seed 2 Funding, Partners with Daiichi Sankyo on Structural Surfaceomics

Immuto Scientific today announced the closing of an oversubscribed $8 million Seed 2 financing round alongside a new drug discovery collaboration with Daiichi Sankyo, a leading global pharmaceutical company. The funding and collaboration represent significant milestones for Immuto as it…

Read MoreImmuto Secures $8M Seed 2 Funding, Partners with Daiichi Sankyo on Structural Surfaceomics